Skip to main content
Erschienen in: European Journal of Medical Research 9/2011

01.12.2011 | Research

Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma

verfasst von: A Höblinger, T Gerhardt, MA González-Carmona, R Hüneburg, T Sauerbruch, V Schmitz

Erschienen in: European Journal of Medical Research | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Background and Aim

PDT is an important palliative option for patients with unresectable extrahepatic cholangiocarcinoma (CC). However, the results published to date reported on studies with no more than 6 (mostly up to 4) PDT procedures. Furthermore, the clinical experience of PDT in combination with chemotherapy is limited. The purpose of this retrospective analysis was to evaluate the feasibility and safety of multiple (4 to 14) settings of PDT, combined with biliary drainage, and (in some cases) with chemotherapy.

Methods

Ten patients with unresectable extrahepatic CC were treated with biliary stenting and at least 4 PDT procedures in our department between 10/2005 and 08/2010.

Results

Ten patients (male/female = 5/5), mean age 68.8 years (range, 54 - 81 years) who received at least 4 PDT procedures were analyzed. All patients underwent endoscopic biliary drainage. Nine patients received metallic stents and one patient a plastic stent. In 4 patients (40%) bilateral metal stenting (JoStent SelfX®) was performed. The mean number of PDT sessions was 7.9 ± 3.9 (range: 4 - 14). Eight patients had elevated bilirubin levels with a mean bilirubin at admission of 9.9 ± 11.3 mg/dL, which had decreased to an average minimum of 1.2 ± 0.9 mg/dL after 3 months. No severe toxicity was noted. Two patients received concomitant chemotherapy (GEMCIS as 1st line, GEMOX plus cetuximab as 2nd line). The median overall survival has not been reached, whereas the estimated survival of all patients was 47.6 months, 95% CI 25.9 - 48.1.

Conclusion

Long-term PDT in patients with extrahepatic CC is feasible and effective and is accompanied - at least in this cohort- by a survival time of more than 2 years.
Literatur
1.
Zurück zum Zitat Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 2009,15(34):4240–62. 10.3748/wjg.15.4240PubMedCentralPubMedCrossRef Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 2009,15(34):4240–62. 10.3748/wjg.15.4240PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Ortner MA: Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr opin gastroenterol 2009,25(5):472–6. 10.1097/MOG.0b013e32832e6e1fPubMedCrossRef Ortner MA: Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr opin gastroenterol 2009,25(5):472–6. 10.1097/MOG.0b013e32832e6e1fPubMedCrossRef
3.
Zurück zum Zitat Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S: Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 2008,10(3):148–54. 10.1007/s12094-008-0172-2PubMedCrossRef Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S: Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 2008,10(3):148–54. 10.1007/s12094-008-0172-2PubMedCrossRef
4.
Zurück zum Zitat Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Müller JM, Hörtnagl H, Lochs H: Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998,114(3):536–42. 10.1016/S0016-5085(98)70537-2PubMedCrossRef Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Müller JM, Hörtnagl H, Lochs H: Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998,114(3):536–42. 10.1016/S0016-5085(98)70537-2PubMedCrossRef
5.
Zurück zum Zitat Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mössner J: Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000,31(2):291–8. 10.1002/hep.510310205PubMedCrossRef Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mössner J: Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000,31(2):291–8. 10.1002/hep.510310205PubMedCrossRef
6.
Zurück zum Zitat Zoepf T, Jakobs R, Arnold JC, Apel D, Rosenbaum A, Riemann JF: Photodynamic therapy for palliation of nonresectable bile duct cancer--preliminary results with a new diode laser system. Am J Gastroenterol 2001,96(7):2093–7.PubMed Zoepf T, Jakobs R, Arnold JC, Apel D, Rosenbaum A, Riemann JF: Photodynamic therapy for palliation of nonresectable bile duct cancer--preliminary results with a new diode laser system. Am J Gastroenterol 2001,96(7):2093–7.PubMed
7.
Zurück zum Zitat Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC: Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc 2001,53(4):500–4. 10.1067/mge.2001.113386PubMedCrossRef Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC: Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc 2001,53(4):500–4. 10.1067/mge.2001.113386PubMedCrossRef
8.
Zurück zum Zitat Dumoulin FL, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G, Sauerbruch T: Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003,57(7):860–7. 10.1016/S0016-5107(03)70021-2PubMedCrossRef Dumoulin FL, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G, Sauerbruch T: Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003,57(7):860–7. 10.1016/S0016-5107(03)70021-2PubMedCrossRef
9.
Zurück zum Zitat Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H: Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003,125(5):1355–63. 10.1016/j.gastro.2003.07.015PubMedCrossRef Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H: Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003,125(5):1355–63. 10.1016/j.gastro.2003.07.015PubMedCrossRef
10.
Zurück zum Zitat Harewood GC, Baron TH, Rumalla A, Wang KK, Gores GJ, Stadheim LM, de Groen PC: Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol 2005,20(3):415–20. 10.1111/j.1440-1746.2005.03582.xPubMedCrossRef Harewood GC, Baron TH, Rumalla A, Wang KK, Gores GJ, Stadheim LM, de Groen PC: Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol 2005,20(3):415–20. 10.1111/j.1440-1746.2005.03582.xPubMedCrossRef
11.
Zurück zum Zitat Shim CS, Cheon YK, Cha SW, Bhandari S, Moon JH, Cho YD, Kim YS, Lee LS, Lee MS, Kim BS: Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 2005,37(5):425–33. 10.1055/s-2005-861294PubMedCrossRef Shim CS, Cheon YK, Cha SW, Bhandari S, Moon JH, Cho YD, Kim YS, Lee LS, Lee MS, Kim BS: Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 2005,37(5):425–33. 10.1055/s-2005-861294PubMedCrossRef
12.
Zurück zum Zitat Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF: Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005,100(11):2426–30. 10.1111/j.1572-0241.2005.00318.xPubMedCrossRef Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF: Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005,100(11):2426–30. 10.1111/j.1572-0241.2005.00318.xPubMedCrossRef
13.
Zurück zum Zitat Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, Tannapfel A, Wittekind C, Mossner J, Hauss J, Wiedmann M: Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006,244(2):230–9. 10.1097/01.sla.0000217639.10331.47PubMedCentralPubMedCrossRef Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, Tannapfel A, Wittekind C, Mossner J, Hauss J, Wiedmann M: Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006,244(2):230–9. 10.1097/01.sla.0000217639.10331.47PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Gollnick SO, Brackett CM: Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010,46(1–3):216–26. 10.1007/s12026-009-8119-4PubMedCentralPubMedCrossRef Gollnick SO, Brackett CM: Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010,46(1–3):216–26. 10.1007/s12026-009-8119-4PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Prasad GA, Wang KK, Baron TH, Buttar NS, Wongkeesong LM, Roberts LR, LeRoy AJ, Lutzke LS, Borkenhagen LS: Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastroenterol Hepatol 2007,5(6):743–8. 10.1016/j.cgh.2007.02.021PubMedCrossRef Prasad GA, Wang KK, Baron TH, Buttar NS, Wongkeesong LM, Roberts LR, LeRoy AJ, Lutzke LS, Borkenhagen LS: Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastroenterol Hepatol 2007,5(6):743–8. 10.1016/j.cgh.2007.02.021PubMedCrossRef
16.
Zurück zum Zitat Fuks D, Bartoli E, Delcenserie R, Yzet T, Celice P, Sabbagh C, Chatelain D, Joly JP, Cheron N, Dupas JL, Regimbeau JM: Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice. J Gastroenterol Hepatol 2009,24(11):1745–52. 10.1111/j.1440-1746.2009.05915.xPubMedCrossRef Fuks D, Bartoli E, Delcenserie R, Yzet T, Celice P, Sabbagh C, Chatelain D, Joly JP, Cheron N, Dupas JL, Regimbeau JM: Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice. J Gastroenterol Hepatol 2009,24(11):1745–52. 10.1111/j.1440-1746.2009.05915.xPubMedCrossRef
17.
Zurück zum Zitat Gerhardt T, Rings D, Höblinger A, Heller J, Sauerbruch T, Schepke M: Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol 2010,48(1):28–32. 10.1055/s-0028-1109983PubMedCrossRef Gerhardt T, Rings D, Höblinger A, Heller J, Sauerbruch T, Schepke M: Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol 2010,48(1):28–32. 10.1055/s-0028-1109983PubMedCrossRef
18.
Zurück zum Zitat Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, Vernadakis S, Trarbach T, Paul A, Kaiser GM: Tumor markers as a diagnostic key for hilar cholangiocarcinoma. European Journal of Medical Research 2010,15(8):357–61.PubMedCentralPubMedCrossRef Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, Vernadakis S, Trarbach T, Paul A, Kaiser GM: Tumor markers as a diagnostic key for hilar cholangiocarcinoma. European Journal of Medical Research 2010,15(8):357–61.PubMedCentralPubMedCrossRef
Metadaten
Titel
Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma
verfasst von
A Höblinger
T Gerhardt
MA González-Carmona
R Hüneburg
T Sauerbruch
V Schmitz
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
European Journal of Medical Research / Ausgabe 9/2011
Elektronische ISSN: 2047-783X
DOI
https://doi.org/10.1186/2047-783X-16-9-391

Weitere Artikel der Ausgabe 9/2011

European Journal of Medical Research 9/2011 Zur Ausgabe